Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Xbrane Biopharma - Filing #679209

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Reserve of exchange differences on translation	—	—	—	10 121 SEK	—	—	10 322 SEK	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	191 815 SEK	—	—	176 990 SEK	—	—	—	—	—
Current assets	—	—	—	461 693 SEK	—	—	513 524 SEK	—	—	—	—	—
Non-current liabilities	—	—	—	155 616 SEK	—	—	29 058 SEK	—	—	—	—	—
Current liabilities	—	—	—	326 557 SEK	—	—	236 569 SEK	—	—	—	—	—
Revenue	—	—	238 729 SEK	—	—	—	—	—	57 618 SEK	—	—	—
Profit (loss) from continuing operations	—	—	322 028 SEK	—	—	—	—	—	168 513 SEK	—	—	—
Profit (loss) from discontinued operations	—	—	66 144 SEK	—	—	—	—	—	4 001 SEK	—	—	—
Profit (loss)	—	—	388 172 SEK	—	388 172 SEK	—	—	—	172 513 SEK	172 513 SEK	—	—
Other comprehensive income	—	—	201,000 SEK	—	—	201,000 SEK	—	—	5 157 SEK	—	5 157 SEK	—
Comprehensive income	0 SEK	0 SEK	388 373 SEK	—	388 172 SEK	201,000 SEK	—	– SEK	167 356 SEK	172 513 SEK	5 157 SEK	– SEK